Our sales force realignment continues to go well. With more than 6 months behind us, our new surgical and vascular teams are gaining traction in their new territories and putting us in good position to add new clinically differentiated products to our portfolio, something that we intend to capitalize on in future quarters.
CareFusion Management Discusses Q4 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts